Irvine, CA, United States of America

Alazar N Ghebremeskel

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 91(Granted Patents)


Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents

Title: Alazar N Ghebremeskel: Innovator in Ocular Implants

Introduction

Alazar N Ghebremeskel is a prominent inventor based in Irvine, CA, known for his significant contributions to the field of ocular implants. With a total of 16 patents to his name, he has made remarkable advancements in the treatment of glaucoma and other ocular conditions.

Latest Patents

His latest patents include an intraocular implant designed for high loading of a prostamide. This biodegradable intraocular implant aims for the immediate and sustained reduction of intraocular pressure, providing a treatment option for glaucoma patients. Another notable patent involves biodegradable alpha-2 agonist polymeric implants. These biocompatible implants incorporate an alpha-2 adrenergic receptor agonist and a polymer to facilitate the extended release of the agonist into the eye, addressing various ocular conditions, including elevated intraocular pressure.

Career Highlights

Alazar is currently associated with Allergan, Inc., where he continues to innovate in the field of ocular health. His work has been instrumental in developing new therapeutic options for patients suffering from glaucoma and other related conditions.

Collaborations

He has collaborated with notable colleagues, including Michael R Robinson and Lon T Spada, contributing to the advancement of ocular implant technologies.

Conclusion

Alazar N Ghebremeskel's innovative work in ocular implants has significantly impacted the treatment of glaucoma and other ocular conditions. His dedication to research and development continues to pave the way for future advancements in this critical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…